TY  - RPRT
TI  - T-cell targeted immunotherapy against the tumor associated antigen survivin (BIRC5) as a potential neoadjuvant immunotherapy for triple negative breast cancer.
AU  - Burkholz, S. R.
AU  - Herst, C. V.
AU  - Carback, R. T.
AU  - Harris, P. E.
AU  - Rubsamen, R. M.
PY  - 2022
DO  - 10.1101/2022.07.25.501455
UR  - https://www.biorxiv.org/content/10.1101/2022.07.25.501455v1
ID  - 10.1101/2022.07.25.501455
ER  -